John Lewis

John Lewis has had a diverse and extensive work experience throughout their career. John began their career in 2006 at the University of Western Ontario as an Assistant Professor, while also holding the position of Robert Hardie Chair in Translational Prostate Cancer Research at the London Health Sciences Centre. In 2012, they became the Founding Chair of the Alberta Prostate Cancer Research Initiative, where they led a team of over 300 scientists and healthcare professionals working on innovative prostate cancer research. During this time, they also served as an Associate Professor and later as a Professor at the University of Alberta, specializing in prostate cancer research and holding the Frank and Carla Sojonky Chair in Prostate Cancer Research.

In 2016, John Lewis ventured into the biotechnology industry, founding and serving as the CEO of several companies. John founded Entos Pharmaceuticals, focused on developing nucleic acid-based therapies using a unique drug delivery system. John also founded OncoSenX, a cancer company targeting solid tumors using a gene therapy platform, and Nanostics Inc, a biotechnology company specializing in non-invasive diagnostic tests. In addition, in 2016, they served as the CSO of Oisin Biotechnologies, concentrating on mitigating age-related diseases.

Notably, John Lewis established Aegis Life, Inc. in 2020, where they serve as the Founder and CEO. Throughout their career, John Lewis has demonstrated expertise in prostate cancer research, biotechnology, and translational oncology.

John Lewis completed their Bachelor of Science degree with Honours in Genetics from Western University, where they studied from 1989 to 1993. John then pursued a Ph.D. in Biochemistry at the University of Victoria from 1996 to 2003. After completing their Ph.D., they went on to pursue a PDF (Postdoctoral Fellowship) at Scripps Research from 2003 to 2006, focusing on the field of Nanotechnology and Imaging.